The 2-year follow-up results from the phase I/II ZUMA-1 trial of patients with refractory large B-cell lymphoma show that the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel remains efficacious and manageable in the long term.
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30864-7 ASH 2018; San Diego, California, USA; 1–4 December
Combining ibrutinib rather than chlorambucil with obinutuzumab significantly improves progression-free survival in previously untreated patients with chronic lymphocytic leukemia, phase III study data show.
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30788-5 ASH 2018; San Diego, California, USA; 1–4 December
Heavily pretreated adults with relapsed or refractory diffuse large B-cell lymphoma respond well to treatment with the chimeric antigen receptor T-cell therapy tisagenlecleucel, show results of the pivotal JULIET trial.
N Engl J Med 2018; doi:10.1056/NEJMoa1804980 ASH 2018; San Diego, California, USA; 1–4 December
Patients with follicular lymphoma who achieve a positron emission tomography-determined complete response to induction immunochemotherapy have a significantly better prognosis than those with a non-complete response, research shows.
The oral, dual inhibitor of phosphoinositide 3-kinase-δ and –γ duvelisib significantly delays disease progression or death compared with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, data from the DUO trial show.
Professor Mel Greaves (Institute of Cancer Research, London, UK) discusses his proposed theory for the etiology of childhood acute lymphoblastic leukemia, in which early microbial exposure plays a key role. (10.21)
Adding lomustine to standard chemotherapy with idarubicin and cytarabine significantly improves survival in fit older patients with favorable- or intermediate-risk acute myeloid leukemia, phase III trial data show.
This month we round-up four hematologic cancer trials, two looking at treatment options for older and younger patients with Hodgkin lymphoma, and two evaluating treatments for smoldering and relapsed or refractory multiple myeloma. Read on to find out more.
Persistent disease-associated mutations detected in the bone marrow 30 days after stem cell transplantation are associated with an increased risk for disease progression among patients with myelodysplastic syndrome, research shows.
Levofloxacin prophylaxis significantly reduces the risk for bacteremia among children receiving intensive chemotherapy for acute leukemia, but not among those undergoing hematopoietic stem cell transplantation, study data show.
Pretreatment levels of circulating tumor DNA, as well as changes during therapy, are independently prognostic of outcomes in patients with diffuse large B-cell lymphoma and can add to established risk factors, findings indicate.
Treatment-naïve follicular lymphoma patients have similar outcomes regardless of whether they receive lenalidomide or chemotherapy in combination with rituximab, suggest phase III trial findings published in The New England Journal of Medicine.
Obinutuzumab and venetoclax, preceded by bendamustine debulking for high tumor loads, shows high response rates without unexpected or cumulative toxicities in patients with chronic lymphocytic leukemia, a phase II trial suggests.
MAVORIC trial results support the use of the C-C chemokine receptor 4-targeted antibody mogamulizumab over the standard of care vorinostat in previously treated patients with mycosis fungoides or Sézary syndrome.